Navigation Links
Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Date:5/8/2012

CAMBRIDGE, Mass., May 8, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals today announced that the United States Patent and Trademark Office has issued patent number 8,168,755 entitled, "Antibodies specific to heterodimers of Bcl-2 family and uses thereof."

The patent provides a novel method for extending Eutropics' BH3 profiling technology, which is exclusively licensed from the Dana Farber Cancer Institute. This technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to know ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs. This new invention by Eutropics provides a method for extending utility of the technology within solid tumors.

Eutropics is currently involved in the commercialization of the BH3 profiling assay. The test is being developed for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients as well as solid cancers. This work is being done in collaboration with the Dana Farber Cancer Institute, UMass Worcester Medical School, MD Anderson Cancer Center, and the NCI/NIH.

Michael Cardone, Co-Founder and CEO of Eutropics commented, "We are very pleased with the progress being made toward the commercial development of BH3 profiling at Eutropics. Gaining protection on this new intellectual property will help extend the process into a broader range of oncology indications. The company has made excellent progress in our clinical studies and is working very hard to provide a tool to help physicians acquire this diagnostic test that will help guide the use of chemotherapies, ultimately leading to better patient outcomes."

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by guiding the use of novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology. This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... ... January 24, 2020 , ... Sierra Instruments, global leader in ... controllers ideal for BioPharm OEMS. Sierra also announces RedyCompact™ flow ... instruments employ high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable no-drift ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and Cardea ... The partners have agreed to co-develop and market a portfolio of CRISPR QC ... programs. Over the longer-term, the parties aim to develop a COBO branded QC ...
(Date:1/10/2020)... N.J. (PRWEB) , ... January 09, 2020 , ... ... in China, today announced its inaugural GenScript Biotech Global Forum on Jan. 14 ... exploring the theme "Cell and Gene Therapy and the Booming China Market," will ...
(Date:1/7/2020)... , ... January 07, 2020 , ... Vuja De Sciences ... progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), ... CEO of Vuja De said, “We are delighted to welcome Chand and Lee as ...
Breaking Biology Technology:
(Date:1/27/2020)... SAN DIEGO (PRWEB) , ... January 27, 2020 ... ... Christopher Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former ... serves as Executive Chairman of Broadline Capital, the global alternative investment firm. ...
(Date:1/23/2020)... ... 2020 , ... GIOSTAR/HEAMGEN has developed and secured ... The red blood cells are made utilizing a bioreactor that permits the production ... replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red ...
(Date:1/10/2020)... ... January 09, 2020 , ... ... spinal solutions, today announced the 510(K) clearance and commercial launch of the latest ... fusion system. , The EVOL®ha-DLIF is made of PEEK-OPTIMA HA Enhanced material ...
Breaking Biology News(10 mins):